Clinical Trials Sponsored by BioGene Pharmaceutical Ltd.

Total 4425 results

BioGene Pharmaceutical Ltd.

Withdrawn

Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis (ELTA)

Endometriosis | Endometriosis Ovary | Endometriosis, Rectum | Endometriosis Externa

Switzerland
Jazz Pharmaceuticals
BeiGene, Ltd.

Active, not recruiting

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers (HERIZON-BTC-01)

HER2-amplified Biliary Tract Cancers

United States, Spain, United Kingdom, Korea, Republic of, Canada, China, Italy, Chile, France
Jazz Pharmaceuticals
BeiGene, Ltd.

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric Neoplasms

Korea, Republic of, Belgium, Netherlands, Spain, Japan, China, Germany, United Kingdom, Malaysia, Taiwan, Portugal, France, Italy, Australia, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Singapore, Poland and more
Biogen
Elan Pharmaceuticals

Completed

Natalizumab Re-Initiation of Dosing

Multiple Sclerosis, Relapsing-Remitting

United States, Canada
Biogen
Elan Pharmaceuticals

Terminated

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Rheumatoid Arthritis

United States, Canada
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Withdrawn

Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy

Crohn's Disease
Biogen
Elan Pharmaceuticals

Completed

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

Pregnancy Exposure Registry for Tysabri®

Multiple Sclerosis | Pregnancy | Crohn's Disease | Prenatal Exposure

United States
Biogen
Elan Pharmaceuticals

Completed

Natalizumab High Titer Immunogenicity and Safety

Multiple Sclerosis

United States
Center Trials & Treatment
BioGene Pharmaceutical

Withdrawn

Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Breast Neoplasm | Advanced or Recurrent Solid Tumors

Albania
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of Choroideremia Study (NIGHT)

Choroideremia

Finland, United States, Canada, Denmark, Netherlands, Germany, United Kingdom, Brazil, France
Kuhnil Pharmaceutical Co., Ltd.
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

Sleep Initiation and Maintenance Disorders

Korea, Republic of
Kuhnil Pharmaceutical Co., Ltd.
Neurim Pharmaceuticals Ltd.

Completed

Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients

Sleep Initiation and Maintenance Disorders

Korea, Republic of
Biogen
Elan Pharmaceuticals

Completed

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue (ENER-G)

Multiple Sclerosis

United States, Puerto Rico
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United Kingdom, United States, Canada, Belgium, Czech Republic, France, Germany, Netherlands
Biogen
Elan Pharmaceuticals

Completed

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Completed

Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

Crohn's Disease

United States, United Kingdom
Biogen
Elan Pharmaceuticals

Terminated

A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

Rheumatoid Arthritis
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Crohn's Disease

United States
Biogen
Elan Pharmaceuticals

Completed

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

Crohn's Disease

United States, Canada
Biogen
Elan Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Terminated

Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) (IRIS)

Leukoencephalopathy, Progressive Multifocal | Immune Reconstitution Inflammatory Syndrome

Germany, United States
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France
Biogen
Elan Pharmaceuticals

Terminated

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Progressive Multifocal Leukoencephalopathy

United States, Brazil, Italy, Spain, Germany
Biogen
Elan Pharmaceuticals

Completed

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients (TIMER)

Relapsing Remitting Multiple Sclerosis (RRMS)

Belgium, Mexico, Poland, Romania, Saudi Arabia, Ukraine
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Crohn's Disease
Biogen
Elan Pharmaceuticals

Completed

Treatment Interruption of Natalizumab (RESTORE)

Relapsing Remitting Multiple Sclerosis

United States, Germany, Spain
Biogen
Elan Pharmaceuticals

Completed

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay. (Cylex)

Multiple Sclerosis

United States
Biogen
Elan Pharmaceuticals

Completed

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States, Germany, Austria, Belgium, France, Israel, Italy
Biogen
Elan Pharmaceuticals

Completed

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
NightstaRx Ltd, a Biogen Company

Enrolling by invitation

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (SOLSTICE)

Choroideremia | X-Linked Retinitis Pigmentosa

United States, United Kingdom, Netherlands, Germany, France, Brazil, Canada, Denmark, Finland
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS)

X-Linked Retinitis Pigmentosa

United States, France, United Kingdom, Finland, Netherlands, Germany, Canada
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Kissei Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.

Completed

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Anemia

Japan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip (FACT LTS & OA)

Osteoarthritis of the Knee or Hip

United States, Bulgaria, Chile, Colombia, Denmark, Estonia, Germany, Hong Kong, Hungary, Italy, Lithuania, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA1)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Hungary, Spain, Germany, United Kingdom, Denmark, Lithuania, Romania, Russian Federation, South Africa, Ukraine
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Unknown

An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

Type 2 Diabetes Mellitus

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease (REASON)

Parkinson's Disease

United States, Spain, Israel, Canada, Norway, United Kingdom
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

Long-Term Evaluation of BIIB067 (Tofersen)

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

United States, Canada, Italy, Belgium, New Zealand, Japan, France, Germany, United Kingdom
Ionis Pharmaceuticals, Inc.
Biogen

Active, not recruiting

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

Angelman Syndrome

United States, Israel, Italy, France, Australia, United Kingdom
Biogen
Ionis Pharmaceuticals, Inc.

Completed

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))

Amyotrophic Lateral Sclerosis

United States, Canada, Belgium, France, Australia, Japan, Denmark, Korea, Republic of, United Kingdom, Germany, Italy, Poland
Center Trials & Treatment
BioGene Pharmaceutical Inc.

No longer available

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Glioblastoma | Glioma of Brain

Bosnia and Herzegovina, Albania, Bulgaria, Croatia, Romania, Russian Federation, Serbia, Switzerland
Biogen
Eisai Co., Ltd.

Completed

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Healthy Volunteers

United States

Clinical Trials Sponsored by BioGene Pharmaceutical Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations